BIOXYNE LIMITED — Capital/Financing Update 2012

Mar 1, 2012

==> picture [223 x 52] intentionally omitted <==

==> picture [37 x 37] intentionally omitted <==

Probiomics Limited ABN 97 084 464 193

Australian Securities Exchange Limited Companies Announcements Office SYDNEY

2 March, 2012

Suite 1 A, Level 2 802 Pacific Highway Gordon NSW 2072

P: +61 2 9844 5422 F: +61 2 9844 5445 W: www.probiomics.com.au

Achievement of Minimum Subscription under Public Offer

Probiomics Limited (ASX: PCC) ( Probiomics ) is pleased to announce that the minimum subscription of $2.2 million under the Public Offer has been achieved.

As a result, bid condition 6 (‘Successful Public Offer’) to the takeover offers made by Probiomics pursuant to a Bidder’s Statement dated 13 December, 2011, has now been fulfilled.

==> picture [136 x 47] intentionally omitted <==

Patrick Ford

Non Executive Chairman

About Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC[® ]

PCC[®] has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics’ commercial objective is to earn royalties from licensing PCC[®] to distribution companies selling products in global markets.

CONTACTS

Mr Ashok Jairath - Chief Financial Officer and Company Secretary Tel: 02 9844 5422

Email ashok.jairath@probiomics.com.au